Log in
SNRI (Serotonin-Norepinephrine Reuptake Inhibitor)

Venlafaxine

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant used primarily for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. Unlike SSRIs, venlafaxine inhibits both serotonin and norepinephrine reuptake in a dose-dependent manner, with serotonergic effects predominating at lower doses and noradrenergic effects emerging at higher doses. The most testable fact is that abrupt discontinuation causes a withdrawal syndrome characterized by dizziness, nausea, paresthesias, and shock-like sensations due to its short half-life.

Practice questionsHigh-yield facts
Drug classSNRI antidepressant
MechanismInhibits serotonin and norepinephrine reuptake, dose-dependent dual action
Main usesMajor depression, GAD, social anxiety, panic disorder
Key adverse effectDiscontinuation syndrome, hypertension at higher doses
7 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Venlafaxine selectively inhibits the reuptake of serotonin and norepinephrine by blocking the serotonin transporter (SERT) and norepinephrine transporter (NET). It has minimal affinity for muscarinic, histaminergic, or alpha-adrenergic receptors, which accounts for its relatively favorable side effect profile compared to tricyclic antidepressants.

The mechanism is dose-dependent: at lower doses (75 mg/day or less), venlafaxine primarily inhibits serotonin reuptake, functioning similarly to an SSRI. At moderate to higher doses (≥150 mg/day), norepinephrine reuptake inhibition becomes clinically significant, providing the dual SNRI effect. This dose-dependent property allows for flexible titration based on clinical response.

Venlafaxine's active metabolite, O-desmethylvenlafaxine (desvenlafaxine), contributes significantly to its pharmacological activity and has similar potency to the parent compound. Unlike some other antidepressants, venlafaxine does not inhibit monoamine oxidase and has weak effects on dopamine reuptake at very high doses.

High-yield for exams
  • Venlafaxine is an SNRI with dose-dependent effects: serotonergic at low doses (<150 mg), dual action at higher doses
  • Most notable for severe discontinuation syndrome (dizziness, paresthesias, brain zaps) due to short 5-hour half-life—always taper slowly
  • Causes dose-related hypertension, especially at doses >150 mg/day; monitor blood pressure regularly
  • Black box warning: increased suicidal ideation in patients <24 years during initial treatment
  • Contraindicated with MAOIs—allow 14-day washout to avoid serotonin syndrome and hypertensive crisis
  • Active metabolite desvenlafaxine contributes significantly to therapeutic effect; CYP2D6 poor metabolizers still respond
  • Increases bleeding risk when combined with NSAIDs, aspirin, or anticoagulants due to antiplatelet effects
  • Useful in treatment-resistant depression and comorbid chronic pain (diabetic neuropathy) due to noradrenergic activity

Indications

Venlafaxine is FDA-approved for:

  • Major depressive disorder (MDD): First-line treatment, particularly effective in patients with melancholic or treatment-resistant features
  • Generalized anxiety disorder (GAD): Extended-release formulation is effective for chronic worry and physical anxiety symptoms
  • Social anxiety disorder (social phobia): Reduces anticipatory anxiety and avoidance behaviors
  • Panic disorder: Decreases frequency and severity of panic attacks

Off-label uses

  • Diabetic neuropathy and chronic pain syndromes (due to noradrenergic effects)
  • Post-traumatic stress disorder (PTSD)
  • Menopausal hot flashes
  • Attention-deficit/hyperactivity disorder (ADHD) when stimulants are contraindicated
  • Migraine prophylaxis

Venlafaxine may be particularly useful in patients with comorbid depression and chronic pain, or in those who have not responded adequately to SSRIs. The extended-release formulation is preferred for most indications due to better tolerability and once-daily dosing.

Pharmacokinetics

Absorption: Well absorbed after oral administration with bioavailability of approximately 45% due to first-pass metabolism. Food does not significantly affect absorption. Extended-release formulations provide steady plasma levels and reduce peak-related side effects.

Distribution: Moderately protein-bound (27-30%). Distributes widely throughout body tissues.

Metabolism: Extensively metabolized in the liver by CYP2D6 to the active metabolite O-desmethylvenlafaxine (desvenlafaxine). CYP3A4 and CYP2C19 play minor roles. CYP2D6 poor metabolizers will have higher parent drug levels and lower metabolite levels, but clinical efficacy is generally maintained.

Elimination: Half-life of venlafaxine is approximately 5 hours, and desvenlafaxine is approximately 11 hours. The relatively short half-life contributes to the risk of discontinuation syndrome if doses are missed. Approximately 87% is excreted in urine as metabolites. Dose adjustment is required in renal impairment (reduce dose by 25-50%) and moderate to severe hepatic impairment.

Time to steady state: 3 days for immediate-release, 3-4 days for extended-release formulations. Clinical response typically begins within 2-4 weeks, with full therapeutic effect by 4-8 weeks.

Adverse effects

Common side effects

  • Gastrointestinal: Nausea (most common, often transient), dry mouth, constipation, decreased appetite
  • Neurological: Headache, dizziness, insomnia, somnolence, tremor
  • Sexual dysfunction: Delayed ejaculation, anorgasmia, decreased libido (20-40% of patients)
  • Cardiovascular: Dose-related increase in blood pressure (monitor at doses >150 mg/day), palpitations, tachycardia
  • Other: Sweating, fatigue, blurred vision, mydriasis

Serious adverse effects

  • Hypertension: Sustained increases in blood pressure occur in 3-13% of patients, particularly at doses ≥300 mg/day. Regular monitoring is required.
  • Serotonin syndrome: Risk increases with concomitant use of other serotonergic agents (SSRIs, MAOIs, triptans, tramadol, linezolid)
  • Discontinuation syndrome: Occurs in up to 78% of patients who abruptly stop treatment. Symptoms include dizziness, nausea, headache, irritability, paresthesias, electric shock-like sensations (brain zaps), and vivid dreams. Taper slowly over weeks to months.
  • Bleeding risk: Increased risk of bleeding, especially with concurrent NSAIDs, aspirin, or anticoagulants
  • Hyponatremia/SIADH: Particularly in elderly patients
  • Seizures: Dose-related risk (0.26% at doses up to 300 mg/day)
  • Angle-closure glaucoma: Mydriasis can precipitate acute attack in susceptible individuals
  • Activation/mania: Can induce manic episodes in bipolar disorder
  • Suicidality: Black box warning for increased suicidal thinking in children, adolescents, and young adults (ages 18-24) during initial treatment

Withdrawal syndrome

The discontinuation syndrome is particularly prominent with venlafaxine due to its short half-life. Symptoms typically begin within 1-3 days of stopping and include sensory disturbances (paresthesias, electric shock sensations), gastrointestinal symptoms, sleep disturbances, affective symptoms (irritability, anxiety), and disequilibrium. To minimize risk, taper gradually over several weeks.

Contraindications and warnings

Absolute contraindications

  • Concurrent use with MAOIs or within 14 days of discontinuing an MAOI (risk of serotonin syndrome and hypertensive crisis)
  • Hypersensitivity to venlafaxine or desvenlafaxine

Relative contraindications and warnings

  • Uncontrolled hypertension: Venlafaxine can elevate blood pressure; control hypertension before initiating therapy
  • Recent myocardial infarction or unstable heart disease: Limited safety data
  • Bipolar disorder: May precipitate manic or hypomanic episodes; use with mood stabilizer if needed
  • Seizure disorder: Lowers seizure threshold (use with caution)
  • Angle-closure glaucoma: Pupillary dilation may trigger acute attack
  • Bleeding disorders: Antiplatelet effect increases bleeding risk

Special populations

Pregnancy: Category C. Third-trimester exposure is associated with neonatal withdrawal syndrome and persistent pulmonary hypertension. Weigh risks versus benefits; if discontinued, taper gradually.

Breastfeeding: Excreted in breast milk. Venlafaxine and desvenlafaxine levels in nursing infants are relatively low, but monitor infant for adverse effects.

Elderly: Increased risk of hyponatremia and falls. Start with lower doses and monitor closely.

Renal/hepatic impairment: Reduce dose by 25-50% in moderate to severe impairment.

Black box warning

All antidepressants, including venlafaxine, carry a black box warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24) during initial treatment. Close monitoring is essential during the first few months and after dose changes.

Drug interactions

Major interactions

  • MAOIs: Contraindicated due to risk of serotonin syndrome. Allow 14-day washout when switching to/from MAOIs. Linezolid and IV methylene blue also pose serotonin syndrome risk.
  • Serotonergic agents: SSRIs, SNRIs, TCAs, triptans, tramadol, fentanyl, tryptophan, St. John's wort increase serotonin syndrome risk
  • Antiplatelet/anticoagulants: NSAIDs, aspirin, warfarin, clopidogrel increase bleeding risk
  • CNS depressants: Alcohol, benzodiazepines, opioids may cause additive sedation

Moderate interactions

  • CYP2D6 inhibitors: Fluoxetine, paroxetine, bupropion, quinidine increase venlafaxine levels (though desvenlafaxine remains active)
  • CYP3A4 inhibitors/inducers: Minimal clinical effect due to minor CYP3A4 involvement, but ketoconazole may increase levels and carbamazepine may decrease them
  • Haloperidol: Venlafaxine increases haloperidol levels
  • Metoprolol and other CYP2D6 substrates: Venlafaxine weakly inhibits CYP2D6; monitor for increased beta-blocker effects

Pharmacodynamic interactions

  • Antihypertensives: Venlafaxine's blood pressure-elevating effect may antagonize antihypertensive medications
  • QT-prolonging drugs: Caution with concurrent use (venlafaxine has weak QT effects)
  • Sympathomimetics: Additive noradrenergic effects may increase blood pressure and heart rate

No significant food interactions. Grapefruit juice does not meaningfully affect venlafaxine metabolism.

Clinical pearls

  • Dose-dependent dual action: Remember that venlafaxine acts primarily as an SSRI at doses <150 mg/day and as a true SNRI at higher doses. This allows clinicians to start with serotonergic effects and add noradrenergic activity by increasing the dose.
  • Monitor blood pressure: Check blood pressure before initiation and regularly during treatment, especially at doses ≥150 mg/day. Sustained hypertension may require dose reduction or antihypertensive therapy.
  • Discontinuation syndrome is prominent: Venlafaxine has one of the highest rates of discontinuation syndrome among antidepressants. Always taper slowly (reduce by 37.5-75 mg every 4-7 days). Consider switching to fluoxetine before discontinuation in difficult cases due to fluoxetine's long half-life.
  • Extended-release preferred: XR formulations reduce peak-related nausea and allow once-daily dosing, improving adherence.
  • Treatment-resistant depression: Venlafaxine is often effective in patients who have failed SSRI trials, possibly due to dual mechanism.
  • Neuropathic pain: The noradrenergic component makes venlafaxine useful for chronic pain conditions, particularly diabetic neuropathy, similar to duloxetine.
  • Suicidality monitoring: Most critical in the first 4-8 weeks of treatment or after dose changes, particularly in patients under 25 years old.
  • Switching antidepressants: When switching from venlafaxine to an MAOI, allow at least 7 days washout. When switching from an MAOI to venlafaxine, allow 14 days.
  • Not a controlled substance: Venlafaxine is not scheduled by the DEA, but physiological dependence (manifesting as discontinuation syndrome) can occur.
  • CYP2D6 polymorphism: Poor metabolizers have higher venlafaxine levels but therapeutic efficacy is generally preserved because the metabolite (desvenlafaxine) is also active.
Mnemonic

VENLAFAXINE discontinuation syndrome: Vertigo/dizziness, Electric shocks (brain zaps), Nausea, Lethargy, Anxiety, Flu-like symptoms, Agitation, eXtra sensory symptoms (paresthesias), Insomnia, Nightmares, Emotional lability

Practice questions

1. A 42-year-old woman with major depressive disorder has been taking venlafaxine 225 mg daily for 6 months with good symptom control. She ran out of medication 3 days ago and now presents to the emergency department with dizziness, nausea, paresthesias in her hands and feet, and describes brief electric shock-like sensations in her head. Vital signs are normal. Physical examination is unremarkable. Which of the following is the most appropriate next step in management?

Answer: B. This patient is experiencing classic venlafaxine discontinuation syndrome, characterized by dizziness, nausea, paresthesias, and electric shock-like sensations (brain zaps). Venlafaxine has a short half-life (5 hours), making it particularly prone to withdrawal symptoms when doses are missed. The most appropriate management is to restart venlafaxine at the previous effective dose, which will rapidly resolve symptoms, followed by a proper taper if discontinuation is desired. CT head is unnecessary as symptoms are clearly related to medication discontinuation. Fluoxetine could eventually be used as a bridge for discontinuation due to its long half-life, but restarting the original medication is the immediate priority. Meclizine treats only one symptom and does not address the underlying cause.

2. A 35-year-old man with generalized anxiety disorder started on venlafaxine extended-release 75 mg daily returns for follow-up after 6 weeks. He reports significant improvement in worry and physical anxiety symptoms but still has some residual symptoms. Blood pressure today is 138/88 mmHg (baseline was 118/76 mmHg). Which of the following best explains the blood pressure elevation?

Answer: B. Venlafaxine causes dose-dependent elevation in blood pressure through norepinephrine reuptake inhibition, which increases synaptic norepinephrine levels and enhances sympathetic tone. While this effect is more prominent at doses ≥150 mg/day, it can occur even at lower doses in some patients. The noradrenergic mechanism distinguishes SNRIs like venlafaxine from SSRIs, which do not typically raise blood pressure. Serotonin does not cause clinically significant vasoconstriction at therapeutic levels. Venlafaxine has minimal alpha-1 blocking activity (unlike some antidepressants that lower blood pressure). There is no evidence of medication non-adherence, and venlafaxine discontinuation would not cause rebound hypertension. Regular blood pressure monitoring is essential, especially when escalating doses.

3. A 28-year-old woman with major depressive disorder has been taking venlafaxine 150 mg daily for 3 months with partial response. Her psychiatrist wants to add another medication to augment antidepressant effect. She was recently prescribed which of the following medications by her primary care physician for migraine prophylaxis. Use of which medication with venlafaxine poses the highest risk of serotonin syndrome?

Answer: C. Amitriptyline, a tricyclic antidepressant, has significant serotonergic activity through serotonin reuptake inhibition. Combining it with venlafaxine (an SNRI) creates substantial risk for serotonin syndrome due to additive serotonergic effects. Serotonin syndrome presents with altered mental status, autonomic instability, and neuromuscular abnormalities and can be life-threatening. While sumatriptan (a serotonin 5-HT1B/1D agonist) carries a theoretical risk, clinically significant serotonin syndrome from this combination is rare and the FDA has revised warnings to reflect lower risk than previously thought. Propranolol (beta-blocker), topiramate (anticonvulsant), and valproic acid do not have serotonergic mechanisms and do not increase serotonin syndrome risk, though other drug interactions may exist.

Frequently asked questions

How does venlafaxine work?

Venlafaxine works by inhibiting the reuptake of both serotonin and norepinephrine in the brain, increasing the availability of these neurotransmitters in the synaptic cleft. At lower doses (typically <150 mg/day), it primarily affects serotonin reuptake similar to SSRIs. At higher doses, it also significantly inhibits norepinephrine reuptake, providing dual SNRI action. This dose-dependent mechanism distinguishes it from pure SSRIs and allows for flexible titration based on patient response.

What are the side effects of venlafaxine?

Common side effects include nausea (most frequent), dry mouth, headache, dizziness, insomnia, sweating, and sexual dysfunction. Venlafaxine can cause dose-related increases in blood pressure, particularly at doses above 150 mg/day, requiring regular monitoring. The most clinically significant issue is severe discontinuation syndrome when stopping abruptly—patients experience dizziness, electric shock-like sensations (brain zaps), nausea, and paresthesias. Other serious but less common effects include serotonin syndrome (when combined with other serotonergic drugs), increased bleeding risk, hyponatremia in elderly patients, and seizures at high doses.

Is venlafaxine a controlled substance?

No, venlafaxine is not a controlled substance and is not scheduled by the DEA. However, it can cause physiological dependence, which manifests as a severe discontinuation syndrome if stopped abruptly. This withdrawal syndrome includes dizziness, nausea, paresthesias, and shock-like sensations, but does not represent addiction or drug-seeking behavior. Patients should always taper venlafaxine gradually under medical supervision rather than stopping suddenly.

Venlafaxine vs duloxetine—what is the difference?

Both venlafaxine and duloxetine are SNRIs that inhibit serotonin and norepinephrine reuptake, but they differ in several ways. Venlafaxine has dose-dependent action (more serotonergic at low doses, dual action at higher doses), while duloxetine has balanced SNRI activity at all therapeutic doses. Duloxetine is FDA-approved for more pain conditions (fibromyalgia, chronic musculoskeletal pain, diabetic neuropathy) and has fewer gastrointestinal side effects. Venlafaxine has a shorter half-life (5 hours vs 12 hours for duloxetine), leading to more prominent discontinuation syndrome. Both require blood pressure monitoring, though venlafaxine's hypertensive effect is more dose-dependent.

Can you drink alcohol while taking venlafaxine?

It is generally recommended to avoid or limit alcohol consumption while taking venlafaxine. Both venlafaxine and alcohol are CNS depressants, and combining them can cause additive sedation, dizziness, impaired coordination, and increased risk of falls. Alcohol can also worsen depression and anxiety, counteracting the therapeutic benefits of venlafaxine. Additionally, alcohol may increase certain side effects like drowsiness and impaired judgment. While occasional light drinking may be tolerated by some patients, heavy or regular alcohol use should be avoided, and patients should discuss their alcohol consumption with their healthcare provider.

Conditions it is used for

Major depressive disorderGeneralized anxiety disorderSocial anxiety disorderPanic disorderDiabetic neuropathyChronic pain syndromesPost-traumatic stress disorderMenopausal hot flashes
DesvenlafaxineDuloxetineFluoxetineSertralineEscitalopramBupropionMirtazapineAmitriptyline

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06AX16

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.